novo integrated sciences inc - NVOS

NVOS

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 28.75K

Last Updated:

Dec 31, 2025, 3:25 PM EDT

Company Overview: novo integrated sciences inc - NVOS

NVOS Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.10

Market Cap

$0.00

Shares Outstanding

19.73M

Public Float

18.43M

Beta

1.34

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.91

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

9.10K

 

NVOS Performance

1 Week
 
440.00%
 
1 Month
 
170.00%
 
3 Months
 
2,600.00%
 
1 Year
 
-94.80%
 
5 Years
 
-99.99%
 

NVOS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About novo integrated sciences inc - NVOS

Novo Integrated Sciences, Inc. engages in the provision of medical services. The firm offers specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, and dental services. Its multi-disciplinary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation, and prevention through its clinics, affiliate clinics, retirement homes, and long-term facilities. The firm operates through the Healthcare Services and Product Sales segments. The company was founded by Michael H. Rouse on November 27, 2000 and is headquartered in Bellevue, WA.

NVOS At a Glance

Novo Integrated Sciences, Inc.
11120 NE 2nd Street
Bellevue, Washington 98004
Phone 1-206-617-9797 Revenue 13.29M
Industry Medical/Nursing Services Net Income -16,166,744.00
Sector Health Services 2024 Sales Growth 5.746%
Fiscal Year-end 08 / 2025 Employees 264
View SEC Filings

NVOS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.427
Price to Book Ratio 0.403
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.74
Enterprise Value to Sales 0.792
Total Debt to Enterprise Value 0.568

NVOS Efficiency

Revenue/Employee 50,357.413
Income Per Employee -61,237.667
Receivables Turnover 4.217
Total Asset Turnover 0.393

NVOS Liquidity

Current Ratio 0.371
Quick Ratio 0.303
Cash Ratio 0.058

NVOS Profitability

Gross Margin 43.195
Operating Margin -62.537
Pretax Margin -121.319
Net Margin -121.606
Return on Assets -47.757
Return on Equity -81.427
Return on Total Capital -77.453
Return on Invested Capital -75.16

NVOS Capital Structure

Total Debt to Total Equity 40.157
Total Debt to Total Capital 28.651
Total Debt to Total Assets 18.607
Long-Term Debt to Equity 10.424
Long-Term Debt to Total Capital 7.437
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Novo Integrated Sciences Inc - NVOS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
9.31M 11.74M 12.57M 13.29M
Sales Growth
+18.38% +26.14% +7.11% +5.75%
Cost of Goods Sold (COGS) incl D&A
7.08M 9.63M 7.62M 7.55M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.37M 3.02M 2.30M 2.26M
Depreciation
766.45K 323.04K 292.04K 259.51K
Amortization of Intangibles
1.60M 2.70M 2.01M 2.00M
COGS Growth
+14.77% +36.03% -20.92% -0.89%
Gross Income
2.22M 2.10M 4.95M 5.74M
Gross Income Growth
+31.58% -5.37% +135.50% +15.95%
Gross Profit Margin
+23.88% +17.92% +39.39% +43.20%
2021 2022 2023 2024 5-year trend
SG&A Expense
6.50M 11.69M 13.51M 14.06M
Research & Development
- - - -
-
Other SG&A
6.50M 11.69M 13.51M 14.06M
SGA Growth
+9.70% +79.93% +15.54% +4.08%
Other Operating Expense
- - - -
-
Unusual Expense
- 99.35K 15.44M (1.83M)
EBIT after Unusual Expense
(4.37M) (25.03M) (8.55M) (6.48M)
Non Operating Income/Expense
67.59K (472.55K) 401.41K (2.42M)
Non-Operating Interest Income
45.69K 169.09K 9.03K 202.53K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
165.00K 7.57M 5.12M 7.23M
Interest Expense Growth
+5.32% +4,486.73% -32.38% +41.22%
Gross Interest Expense
165.00K 7.57M 5.12M 7.23M
Interest Capitalized
- - - -
-
Pretax Income
(4.47M) (33.07M) (13.27M) (16.13M)
Pretax Income Growth
+9.21% -639.61% +59.87% -21.55%
Pretax Margin
-48.05% -281.71% -105.55% -121.32%
Income Tax
- - - (22.30K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(4.47M) (33.05M) (13.27M) (16.13M)
Minority Interest Expense
(8.79K) (195.96K) (54.89K) 38.17K
Net Income
(4.46M) (32.85M) (13.21M) (16.17M)
Net Income Growth
+9.22% -636.18% +59.77% -22.34%
Net Margin Growth
-47.95% -279.86% -105.11% -121.61%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(4.46M) (32.85M) (13.21M) (16.17M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(4.46M) (32.85M) (13.21M) (16.17M)
EPS (Basic)
-1.8011 -11.2796 -1.2999 -0.8966
EPS (Basic) Growth
+15.60% -526.26% +88.48% +31.03%
Basic Shares Outstanding
2.48M 2.91M 10.17M 18.03M
EPS (Diluted)
-1.8011 -11.2796 -1.2999 -0.8966
EPS (Diluted) Growth
+15.60% -526.26% +88.48% +31.03%
Diluted Shares Outstanding
2.48M 2.91M 10.17M 18.03M
EBITDA
(1.91M) (6.57M) (6.25M) (6.05M)
EBITDA Growth
+15.10% -244.34% +4.82% +3.17%
EBITDA Margin
-20.49% -55.95% -49.72% -45.53%

Novo Integrated Sciences Inc in the News